Oral Corticosteroid Reduction Between Biologics Initiated and Non-Initiated Patients with Severe Asthma.

Tanaka, Akihiko; Takahashi, Mai; Fukui, Ayako; Arita, Yoshifumi; Fujiwara, Masakazu; Makita, Naoyuki; Tashiro, Naoki

Tanaka, Akihiko; Takahashi, Mai; Fukui, Ayako; Arita, Yoshifumi; Fujiwara, Masakazu; Makita, Naoyuki; Tashiro, Naoki.

Afiliação

Tanaka A; Division of Respiratory Medicine and Allergology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
Takahashi M; Medical, AstraZeneca K.K., Tokyo, Japan.
Fukui A; Medical, AstraZeneca K.K., Osaka, Japan.
Arita Y; Medical, AstraZeneca K.K., Osaka, Japan.
Fujiwara M; Medical, AstraZeneca K.K., Osaka, Japan.
Makita N; Medical, AstraZeneca K.K., Osaka, Japan.
Tashiro N; Medical, AstraZeneca K.K., Osaka, Japan.

J Asthma Allergy ; 16: 839-849, 2023.

Article em En | MEDLINE | ID: mdl-37600852

Palavras-chave

asthma exacerbation; biologics; oral corticosteroid; retrospective cohort study; severe asthma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: J Asthma Allergy Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google